Inhalation

INH1026

Issue link: https://www.e-digitaleditions.com/i/1546950

Contents of this Issue

Navigation

Page 38 of 43

Inhalation OctOber 2026 37 Development of sustainable respiratory drug delivery solutions Collaborating for two decades with pharmaceutical companies, CDMOs and start-ups on the develop- ment of DPIs, pMDIs and nebulizers. Gaining early insights into how a medical device will meet the needs of patients and caregivers is crucial to maintaining development timelines. Prior PLM Medical combines advanced computational simulations with a range of visualization techniques and rigorous physical testing to ensure that only the most viable concepts advance. (See the video linked below.) is targeted approach focuses resources and shortens the design cycle. Dis- cover how we can support you to de-risk the devel- opment process, accelerate your time to market and deliver for patients. Prior PLM Medical Ireland: +353 71 9620980 info@priors.com www.priors.com Inhalation expertise from discovery to delivery Phillips Medisize specializes in innovative inhaled drug development, leveraging more than 25 years of experience to help bring your medicines to market. Our expertise spans small molecules, biologics, com- plex combinations and generic products for pMDI, DPI, nasal inhaler and nebulization devices. Our customizable platform products help you accelerate development timelines, minimize risk and optimize costs. You can rely on our world-class engineering team to tailor solutions to your needs. By investing in advanced technologies, we bring award-winning approaches to the toughest engineering challenges— always aligning our work with your objectives. Phillips Medisize US: 715 232-0942 PMCInfo@molex.com www.phillipsmedisize.com CLICK HERE TO START OR RENEW YOUR FREE SUBSCRIPTION

Articles in this issue

Links on this page

view archives of Inhalation - INH1026